首页> 外文期刊>Journal of nuclear cardiology: official publication of the American Society of Nuclear Cardiology >Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.
【24h】

Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.

机译:运动性心肌灌注显像在高峰运动时辅助性瑞加德森注射的安全性和可行性:“运动和瑞加德森压力测试(BERST)”试验。

获取原文
获取原文并翻译 | 示例
       

摘要

The data existing in the literature regarding the safety of using regadenoson with symptom-limited exercise are limited, which motivated the authors to undertake this randomized study.We offered patients scheduled to undergo vasodilator stress nuclear myocardial perfusion imaging the opportunity to exercise instead. Patients who failed to reach target heart rate (THR) were randomized to (1) receive regadenoson at peak exercise or (2) stop exercise and receive regadenoson at rest. Patients who reached THR received a standard Tc-99m sestamibi injection with no regadenoson.200 patients were included (66% male, mean age 52.5?±?13.6). 125 patients (62%) reached THR with exercise alone. All stress protocols were well tolerated, and there were no significant adverse events. There were no statistically significant differences in the extent of perfusion abnormalities, image quality, or rate of referral to cardiac catheterization within 60?days between the groups. In fully adjusted logistic regression models, beta-blocker use and diabetes remained significant univariate predictors of failure to reach THR (OR 0.21, 95% CI 0.1-0.5, P?
机译:文献中关于使用瑞加狄森进行有症状限制运动的安全性的数据有限,这促使作者进行了这项随机研究。我们为计划接受血管舒张应激性心肌灌注成像的患者提供了运动的机会。未能达到目标心率(THR)的患者被随机分为(1)在运动高峰期接受regadenoson或(2)停止运动并在休息时接受regadenoson。达到THR的患者接受了标准的Tc-99m司他他比注射,没有再加腺苷。其中包括200名患者(66%的男性,平均年龄52.5±13.6岁)。仅运动一项即可达到THR的患者为125名(62%)。所有压力方案均耐受良好,没有明显的不良事件。两组之间在60天内的灌注异常程度,图像质量或心脏导管检查转诊率没有统计学差异。在完全调整的logistic回归模型中,β受体阻滞剂的使用和糖尿病仍然是未能达到THR的重要单变量预测因子(OR 0.21,95%CI 0.1-0.5,P 。0001,OR 0.34,95%CI 0.2-0.7, P?= ?. 004)。将无法达到THR的患者在运动高峰期进行瑞格狄森治疗与运动相结合的方案是可行的,耐受性良好的,并且可产生与静止时标准瑞格狄森注射相当的成像结果。此外,在当前的临床实践中,药理学压力测试可能会被过度订购,因为接受这种测试的患者经常能够锻炼身体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号